Celltrion reported Q2 consolidated revenue of 1.3937 trillion won and operating profit of 451.8 billion won, with year-over-year growth of 45% and 86.3% respectively, according to a disclosure on the day prior to July 28. The operating profit exceeded the consensus estimate of 400.7 billion won by 12.75%, prompting multiple securities firms to raise their target prices for the stock. The earnings surprise was driven by rapid growth in high-margin new products and operating leverage from the company's North American direct sales structure. On July 28, Celltrion shares closed at 177,400 won, down 0.73%, outperforming the broader market as the KOSPI and KOSDAQ indices plunged 10.84% and 7.72% respectively. Analysts attributed the relative resilience to upgraded target prices following the strong Q2 performance, with the consensus target rising 3.24% to 274,784 won.
Celltrion Reports Q2 Operating Profit of 451.8 Billion Won
Celltrion's Q2 consolidated revenue reached 1.3937 trillion won, up 45% year-over-year, while operating profit of 451.8 billion won represented an 86.3% increase compared to the same period last year. The operating profit figure surpassed the pre-announcement consensus of 400.7 billion won by 12.75%. New product revenue totaled 824.9 billion won, a 76.0% year-over-year increase, accounting for 65% of total biosimilar sales. The company's profitability improvement was attributed to the rapid growth of high-margin new products and fixed-cost leverage effects from its North American direct sales structure.
Securities Firms Raise Target Prices Following Earnings Beat
Shinhan Investment Securities raised its target price from 276,418 won to 290,000 won, Mirae Asset Securities increased its target from 260,000 won to 280,000 won, NH Investment Securities adjusted upward from 260,000 won to 270,000 won, and Meritz Securities lifted its target from 266,887 won to 290,000 won. According to financial data provider FnGuide, the consensus target price for Celltrion stood at 274,784 won as of the reporting date, representing a 3.24% increase from the previous day. Kim Jun-young, a researcher at Meritz Securities, stated that "the visibility of profit growth has significantly increased as high-margin new products grow rapidly while operating leverage from North American direct sales costs materializes in earnest."
Omniclo Achieves 21% European Market Share in Third Quarter Post-Launch
Omniclo, a biosimilar of Xolair (omalizumab), recorded revenue of 116.7 billion won in Q2 alone. The product achieved a 21% market share in Europe within three quarters of launch, benefiting from its status as the sole first-mover in the market. Jeong Jae-won, a researcher at iM Securities, commented that "Omniclo, which preempted a market without competition, clearly demonstrated the advantages of a first-mover," adding that "while the earnings content remains intact, the quality is improving every quarter." Kim Min-jeong, a researcher at DS Investment Securities, projected that "this year will be a year of accelerated earnings growth as sales of subsequently launched biosimilars increase in earnest."
Analysts Cite Valuation Discount Versus Global Peers
Kim Seung-min, a researcher at Mirae Asset Securities, analyzed that "Celltrion is significantly undervalued compared to Sandoz, a global leading biosimilar company, considering that 65% of Sandoz's revenue comes from low-margin generics and its business is centered on contract manufacturing (CMO), whereas Celltrion has completed its own production system from the beginning and is recording an unmatched operating margin of over 30%." Han Seung-yeon, a researcher at NH Investment Securities, stated that Celltrion "possesses both overwhelming earnings growth and unprecedented valuation appeal, allowing investors to expect both defensive and growth stock roles in an uncertain market."
FAQ
What were Celltrion's Q2 financial results?
Celltrion reported Q2 consolidated revenue of 1.3937 trillion won and operating profit of 451.8 billion won, representing year-over-year increases of 45% and 86.3% respectively. The operating profit exceeded the consensus estimate of 400.7 billion won by 12.75%.
How did Omniclo perform in the European market?
Omniclo, Celltrion's biosimilar of Xolair, generated 116.7 billion won in Q2 revenue and captured a 21% market share in Europe within three quarters of its launch, benefiting from its first-mover advantage in a market without competition.
